Claim and evidence Close ×
Generate Biomedicines' IPO prospectus (26 February 2026) states that it was enrolling patients in two Phase 3 clinical trials of GB-0895 for severe asthma, initiated in December 2025, and that "the first patient was dosed" in the SOLAIRIA-1 Phase 3 trial on 26 January 2026. Copy claim link
Copy claim reference
Machine-checked, not reviewed by an editor Stated in source Supported
Supporting evidence: primary · 1 source
Provision Statement · provision ID co-generate-gb0895-phase3-2026 Date 2026-02-26 · publication Records dated 2026 → Scope and limits The company's statement of a candidate's trial status; it is not a registry record or an independent result. The prospectus describes GB-0895 as one of its "computationally engineered proteins"; how far AI contributed to the candidate is the company's characterisation and is not assessed here.
The evidence 02 primary source Supports the claim
Generate Biomedicines, Inc. prospectus (Rule 424(b)(4)), initial public offering of common stock ↗ Generate Biomedicines, Inc. (filed with the US SEC) · 2026-02-26
Copy source reference
Cite the original source Cite the original document, not Selekoa. Check these details against it.
Copy APA
Download BibTeX Download RIS Download CSL-JSON
Source excerpt “We are currently enrolling patients in two parallel global Phase 3 clinical trials for GB-0895 initiated in December 2025 (SOLAIRIA-1 and SOLAIRIA-2) for severe asthma, with full enrollment expected by the first half of 2028.” Location in source Prospectus summary, "Overview"
How it was read Retrieved directly from the publisher
Machine-checked · 2026-10-30
Source details and check notes Authors Generate Biomedicines, Inc. (filed with the US SEC) Version Retrieved for the candidate pack on 2026-10-30 (SHA-256 ca57aeb45111477c90d801e907d1999257ae15cc1ed3901b6317a77907c83d37). SEC EDGAR 424B4, accession 0001193125-26-083190, filed 2026-02-27; prospectus dated February 26, 2026; as served on 2026-10-30. Canonical address Open the canonical source ↗ Accessed 2026-10-30 Language English (en) Attribution Generate Biomedicines, Inc. (filed with the US SEC), “Generate Biomedicines, Inc. prospectus (Rule 424(b)(4)), initial public offering of common stock”, 2026-02-26. Reuse No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution. Check notes Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (35 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. No human editorial review. primary source Supports the claim
Generate Biomedicines, Inc. prospectus (Rule 424(b)(4)), initial public offering of common stock ↗ Generate Biomedicines, Inc. (filed with the US SEC) · 2026-02-26
Copy source reference
Cite the original source Cite the original document, not Selekoa. Check these details against it.
Copy APA
Download BibTeX Download RIS Download CSL-JSON
Source excerpt “The first patient was dosed in our SOLAIRIA-1 Phase 3 clinical trial on January 26, 2026.” Location in source Prospectus summary, "Overview"
How it was read Retrieved directly from the publisher
Machine-checked · 2026-10-30
Source details and check notes Authors Generate Biomedicines, Inc. (filed with the US SEC) Version Retrieved for the candidate pack on 2026-10-30 (SHA-256 ca57aeb45111477c90d801e907d1999257ae15cc1ed3901b6317a77907c83d37). SEC EDGAR 424B4, accession 0001193125-26-083190, filed 2026-02-27; prospectus dated February 26, 2026; as served on 2026-10-30. Canonical address Open the canonical source ↗ Accessed 2026-10-30 Language English (en) Attribution Generate Biomedicines, Inc. (filed with the US SEC), “Generate Biomedicines, Inc. prospectus (Rule 424(b)(4)), initial public offering of common stock”, 2026-02-26. Reuse No open redistribution licence asserted. Bibliographic metadata, editorial paraphrases and short attributed quotations (at most 50 words each). Recheck terms before wider redistribution. Check notes Candidate pack passage, AI in biology (research/ai-in-biology). The quotation (16 words) matched the text retrieved for the candidate pack on 2026-10-30. Matching ignored differences of whitespace, case, quotation marks, dashes and Unicode compatibility forms, so the source’s typography can differ. No human editorial review. Status and meaning Editorial status. Not reviewed by an editor . An exploratory record that no editor has accepted. This status does not say whether a person has read any linked passage. Each evidence record above shows how it was checked.
Relation. An exact framework edition, or another document with an exact expression, states one provision: a capability threshold or risk level and its trigger, a required safeguard or action, a decision authority (who decides, recommends, can overrule or is informed), a stated exception, or another statement of its content, such as a licence term or a prospectus statement. The passage records what the document says, not implementation, compliance or effectiveness. Provisions with the same key align across editions of one family.
Date. Dated by the prospectus that states it; the dosing date (2026-01-26) and initiation month (December 2025) are the company's statements within it.
Record ID aib-co-generate-gb0895-phase3-2026